Kornimate/medical-research-clean huggingface dataset:
mri study of the distal radius bone marrow fat fraction in osteoporotic and healthy women

Conditions: Osteoporosis, Postmenopausal

Summary: the aim of the study is to test whether the distal radius bone marrow show significant difference in the fat fraction in young women compared to post menopausal women with and without osteoporosis.

patients of the department of endocrinology, who routinely perform bone density tests, dxa (dual energy x-ray absorpiometry) test on the lumbar spine, proximal femoral and distal radius, will be invited for a visit, and after signing the informed consent form, the following data will be collected: age, bmi, first menstrual period and last menstrual period, family history of osteoporosis, history of osteoporotic fractures, smoking, alcohol use and exercise habits. in addition, blood tests will be performed: calcium phosphate, albumin, alkaline phosphatase, vitamin d level, thyroid function, lh (luteinizing hormone) fsh (follicle stimulating hormone), estradiol, and serum bone turnover index (ctx p1np). amount of blood taken: 12 ml the patients will then be sent to the alfredo federico strauss center for computerized neuroimaging at tel aviv university for an mri study of the distal radius. the study results will be analyzed by an expert bone radiologist from the sourasky medical center to reject any kind of pathology (such as a fracture, inflammation, tumor), and further analyzed for bone marrow fat fraction by tel aviv university researchers. in the case of abnormal findings, they will be mentioned in the report and the participants will receive recommendations from the appropriate expert.

Eligibility criteria:
inclusion criteria: women over the age of 45 with regular menstruation should be included in group 1, women over the age of 55 without menstruation for at least one year should be included in groups 2 or 3 according to the results of the bone density test. if t-score\> -2.5 will be included in group 2 and if t-score \<-2.5 they will be included in group 3. - exclusion criteria: women with metabolic bone disease, thyroid or pre-thyroid disease, diabetes, chronic steroid use, use of osteoporosis drugs, hormonal therapy, bmi below 20 or over 27, pregnant women and tattooed women in the area under study will not be included in the study. -

Keywords: osteoporosis mri distal radius postmenopausal
accuracy of pulse oximeters with profound hypoxia at rest (niho17)

Conditions: Hypoxia

Summary: the aim of this study is to determine the accuracy of devices called pulse oximeters, which measure blood oxygen by shining light through fingers, ears or other skin, without requiring blood sampling. study will be used with patients at rest.

this study is intended to evaluate performance of a new design pulse oximeter (test device) manufactured by nihon kohden corporation sufficiently to support performance claims for an fda 510k submission or iso technical file. specifically, spo2 and pulse rate accuracy will be assessed for a nihon kohden olv-4202 pulse oximeter with adult patients under a controlled setting of varying levels of inhaled oxygen concentration levels for patients at rest.

Eligibility criteria:
inclusion criteria: * both male and female subjects who can give written informed consent * healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile * meeting the demographic requirements exclusion criteria: * age below 18 or over 50 * pregnant women * significant arrhythmia * blood pressure above 150 systolic or 90 diastolic * carboxyhemoglobin levels over 3% * subjects whom the investigator consider ineligible for the study
validity and reliability of the turkish version of the pectus carinatum body image quality of life questionnaire for patients with pectus carinatum

Conditions: Pectus Carinatum; Quality of Life; Body Image; Brace

Summary: in children with severe pectus carinatum, a significant loss of self-esteem, impairment in social behavior due to a decrease in quality of life associated with physical appearance and mental health has been reported. however, a questionnaire measuring these problems specific to this disease is not available in turkish. therefore, in our study, we aimed to investigate the validity and reliability of the pectus carinatum body image quality of life questionnaire (pecbi-qol) in patients with pectus carinatum.


Eligibility criteria:
inclusion criteria: 1. patients who have been diagnosed with pectus carinatum by a doctor (2 cm above the protrusion level) 2. between the ages of 10-18, 3. having dissatisfaction with this defect exclusion criteria: 1. having severe scoliosis (cobb angle over 20 degrees) 2. having chronic systemic disease 3. having a serious psychiatric illness 4. having complex mixed type pectus deformity
a pilot study assessing emsam in bipolar depression

Conditions: Bipolar Depression

Summary: this pilot study will evaluate the efficacy of the monoamine oxidase inhibitor (maoi)emsam, a selegiline transdermal system (sts), in bipolar depression.

most current treatments for bipolar depression have been shown to be of modest effectiveness. there is some literature which suggests that monoamine oxidase inhibitors (maois) have greater efficacy than tricyclic antidepressants, and that they are effective for treatment-resistant depression of all types, both unipolar and bipolar. the maoi selegiline has demonstrated antidepressant efficacy. emsam, a selegiline transdermal system, provides central nervous system but not intestinal/liver mao inhibition without clinically significant increases in sensitivity to dietary tyramine. this transdermal system appears to be associated with fewer side effects and increased safety relative to oral maoi's. this pilot study will evaluate the efficacy of emsam in bipolar depression.

Eligibility criteria:
inclusion criteria: 1. ages 18 - 65 2. dsm-iv bipolar disorder (i, ii, nos), depressed phase 3. dsm-iv bipolar disorder (i,ii, nos), mixed state with adequate mood stabilization (ie, resolution of manic or hypomanic symptoms for 8 weeks with a minimum of 4 weeks on a stable dose of mood-stabilizing medication that will be continued through all phases of the study). 4. prior failure of or inability to tolerate at least one other antidepressant treatment 5. physically healthy 6. agrees to participate in the study 7. ham-d 24 \> 10 exclusion criteria: 1. bipolar disorder (i, ii, nos), mixed state without adequate mood stabilization 2. prior significant adverse reaction to emsam 3. unstable medical disorder 4. history of epilepsy (febrile seizure o.k.) 5. current use of any medication that might interact with ensam. 6. use within 2 weeks of other antidepressant medication (6 weeks for fluoxetine) 7. inability to adhere to a tyramine-free diet 8. recent (past 6 months) suicide attempt 9. serious suicidal ideation 10. pregnant 11. breast feeding 12. fecund, sexually active females, without adequate contraception 13. prior failure to respond to 2 or more adequate oral maoi trials (2/3 pdr maximum dose, minimum 4 weeks) 14. non-nicotine substance abuse/dependence within the past 6 months (1 year for amphetamines/cocaine)

Keywords: bipolar depression
monolithic zirconia full-mouth implant supported rehabilitation behavior

Conditions: Endosseous Dental Implant Failure; Accident Caused by Broken Ceramic

Summary: in patients that did a full mouth implant supported rehabilitation does cad/cam monolithic zirconia compared to cad/cam zirconia suprastructure (zirconium oxide (yttrium - partially stabilized with tetragonal polycrystalline structure) veneered with feldspathic ceramic, has less post-insertion complications after at least 1-year follow-up ?

study the behavior of implant supported rehabilitations made from full-zirconium dioxide (monolithic with buccal veneer (mz) or full contour monolithic (fcmz) ) and zirconia veneered with feldspathic (pvz) in full-mouth type of rehabilitations (maxilla and mandible). in a private clinic we will record the behavior, regarding prosthodontic and biological complications in different groups (mz vs fcmz vs pvz) after at least 1 year in function. we will make calibration of the investigators for prosthodontic and biological assessement and accepting an inter-observer agreement (kappa) of 0.9 for each parameter. recording will be made without the help of magnifying utilities such as magnifying glasses or optical microscopes.

Eligibility criteria:
inclusion criteria: * maxilla and/or mandible implant full-mouth restoration * monolithic ceramic or zirconia-feldspathic restoration * be at least 18 years of age; * present no systemic or local absolute contraindications for endosseous implant placement; * at least 1 year follow-up exclusion criteria: * the presence of any systemic disease or condition that could compromise postoperative healing or osseointegration. * not full mouth rehabilitation

Keywords: monolithic zirconia zirconia-feldspathic zirconia dental implants fracture chipping
music therapy as an adjunct in cied lead extraction procedures

Conditions: C.Surgical Procedure; Stress; Pain, Procedural; Anxiety

Summary: the study will investigate possible effects of music therapy as an adjunct in an invasive cardiac procedure where infected or broken pacemaker leads, or leads from implantable cardioverter-defibrillators are removed from inside the heart through the vein. the procedure is performed in local anaesthesia with the patient awake. analgesic and anxiolytic drugs are given at the start of the procedure, and repeated if needed. in spite of the drugs, most patients will experience som degree of pain and/or anxiety and increased stress during the procedure. the music therapy intervention contains individually facilitated music listening and coping techniques, aiming to regulate stress responses. the music listening and guidance is provided by a certified music therapist before, during and after the invasive procedure.

see study protocol

Eligibility criteria:
inclusion criteria: 1. planned pacemaker or intracardiac defibrillator (icd) lead extraction performed in local anaesthesia. 2. lead implanted \> 12 months ago 3. able to speak and read norwegian 4. willing to participate all inclusion criteria must be fulfilled. exclusion criteria: 1. significant hearing impairment 2. previous and/or acute psychiatric diagnosis 3. cognitive and mental deficits or impaired functioning
abiraterone and prednisone or darolutamide for the treatment of advanced prostate cancer

Conditions: Advanced Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8

Summary: this phase ii trial compares the effects, good and/or bad of abiraterone and prednisone or darolutamide alone in treating patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). androgens (male hormones) can cause the growth of prostate tumor cells. abiraterone acetate lowers the amount of androgens made by the body. this may help stop the growth of prostate tumor cells that need androgen to grow. darolutamide blocks the use of androgens by the tumor cells. prednisone is used to lessen inflammation and lower the body's immune response. researchers want to compare the side effects of standard of care (soc) abiraterone and prednisone or darolutamide alone in treating patients with advanced prostate cancer.

primary objective: i. tolerability. secondary objectives: i. tolerability in prespecified subpopulations. ii. prostate-specific antigen (psa) response at 7 months. outline: patients are assigned to 1 of 2 arms per treating physician preference. arm i: patients receive abiraterone and prednisone per soc. treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. patients also undergo collection of blood samples during screening and on study. arm ii: patients receive darolutamide per soc. treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. patients also undergo collection of blood samples during screening and on study. after completion of study intervention, patients are followed up for a total of 3 years.

Eligibility criteria:
inclusion criteria: * ability to understand and willingness to sign an informed consent form * histologically confirmed prostate adenocarcinoma * advanced prostate cancer appropriate for treatment with abiraterone acetate plus prednisone or darolutamide as assessed by the treating physician * participants are encouraged to be currently treated with androgen deprivation therapy (adt) or having undergone bilateral orchiectomy * performance status 0 - 2 (karnofsky ≥ 50%) * age ≥ 18 years at time of consent * life expectancy ≥ 6 months per investigator discretion * ability and stated willingness to adhere to the study visit schedule and other protocol procedures/requirements for the duration of the study exclusion criteria: * have been on either abiraterone or darolutamide for \> 28 days prior to initiating enrollment * any condition that in the opinion of the investigator would prohibit the understanding or rendering of informed consent or interfere with the participant's safety or compliance while on trial
to compare the efficacy and safety of tripterygium (tw) versus valsartan in the diabetic nephropathy (dn)

Conditions: Diabetic Nephropathy

Summary: the purpose of this study is to compare the efficacy and safety of tripterygium (tw) versus valsartan (arb) in the diabetic nephropathy (dn).

diabetic nephropathy with heavy proteinuria have high risks of progressing to end stage renal disease. though recent studies have shown that acei or arb could reduce proteinuria of dn and slowed the progression to esrd. but arbs can only reduce proteinuria about 30%, so some patients still have heavy proteinuria,and then loss their renal function rapidly. so, to reduce the proteinuria of dn is a very important therapy target. tripterygium (tw) is a chinese traditional patent drug, it can reduce proteinuria of chronic glomerular nephritis. so, we designed this randomized, prospective clinical trial to assess the efficacy and safety of tw versus arb in the treatment of heavy proteinuria of dn.

Eligibility criteria:
inclusion criteria: 1. a new diagnosis of diabetic nephropathy proved by histology and(or) serology. 2. proteinuria \> 2.5 g/24 h 3. serum creatinine \< 3 mg/dl 4. age 35-65 years exclusion criteria: 1. co-existence of anther chronic glomerular nephritis. 2. severe disfunction of the liver 3. white blood cell \< 3000/ul 4. severe infection in the past 1 month 5. malignant hypertension which in hard to control 6. myocardial infarct or heart failure or sever cerebral vessels complication in the past 6 month

Keywords: tw valsartan treatment diabetic nephropathy proteinuria
contribution of drug induced sleep endoscopy of pediatric obstructive sleep apnea hypopnea syndrome

Conditions: Obstructive Sleep Apnea Hypopnea Syndrome

Summary: the role of drug-induced sleep endoscopy (dise) in the management of obstructive sleep apnea hypopnea syndrome (osahs) is not precisely defined for children. the primary objective of this study was to describe the consequences of dise in the therapeutic management for children with osahs. the secondary objectives were to analyze the correlation between the number of obstructive sites found during dise, the value of apnea-hypopnea index (ahi), and the type of osahs.

retrospective single center study of 31 children (mean age: 5.5 ± 2.6 years) who benefited from dise between 2015 and 2018 in the management of osahs. modification of therapeutic management was noted. a correlation between the number of obstructive sites and the iah on the one hand, and between the number of obstructive sites and the type of sahos on the other hand, was sought.

Eligibility criteria:
inclusion criteria: - osahs confirmed by overnight sleep monitoring (respiratory polygraphy or overnight polysomnography) exclusion criteria: - lack of data

Keywords: drug-induced sleep endoscopy pediatric obstructive sleep apnea hypopnea syndrome tongue base epiglottis occult laryngomalacia lingual tonsillectomy epiglottopexy aryepiglottic folds division
serum cystatin c for early detection of acute kidney injury after primary percutaneous coronary intervention

Conditions: Acute Kidney Injury

Summary: this study aims to evaluate whether the serum levels of cystatin c (cysc) can be used as early biomarkers for the identification of patients who are prone to aki after cardiac interventional surgeries as primary percutaneous coronary intervention (pci)

acute kidney injury (aki) is defined as an absolute increase in serum creatinine ≥0.3 mg/dl (≥26.4 μmol/l), a percentage increase in serum creatinine ≥50% (1.5-fold from baseline), or a reduction in urine output (documented oliguria \ 6 hours) serum creatinine which is considered the gold standard currently for diagnosis of aki remains unchanged until 50% of kidney function falls down. it is affected by non-specific factors like diet, age, dehydration, muscle mass, gender, and drugs there were evidences of the association between aki and acute coronary syndrome (acs); first, aki detection may be missed by cardiologists. physicians tend to disregard mild or transient serum creatinine elevation during hospital stay for acs, and they often attribute small serum creatinine increases to laboratory variations. cystatin c (cysc), a cystatin protease inhibitor, is less affected by non-specific factors. when gfr decreases, cysc begins to increase. cysc was recommended to be measured in addition to creatinine in gfr estimation.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years. 2. patient with absolute increase in serum creatinine ≥0.3 mg/dl (≥26.4 μmol/l) or with percentage increase in serum creatinine ≥50% (1.5-fold from baseline) 3. patient with reduction in urine output (documented oliguria \ 6 hours) 4. patient with typical chest pain, ecg changes, echocardiogram positive finding exclusion criteria: 1. history of nephrectomy 2. patient with renal transplantation 3. patient with renal replacement therapy initiated before admission 4. patient with chronic kidney disease 5. patient on regular haemodialysis 6. patient known to be diabetic
liver-gut axis study through identification of liver disease-specific microbiome

Conditions: Autoimmune Hepatitis; Primary Sclerosing Cholangitis; Non-Alcoholic Fatty Liver Disease; Liver Abscess; Primary Biliary Cirrhosis

Summary: in this study, we aim to identify gut microbiomes specific to patients with chronic refractory liver disease and to conduct a gut-liver axis study on the pathogenesis and disease progression.

1. the investigators will recruit study participants aged 19 and older who have been diagnosed with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic steatohepatitis, or liver abscess, along with their household members, and who have agreed to participate in this study at chungnam national university hospital. 2. the investigators collect and analyze blood and stool samples from the patients and their household members 3. sampling method: non-probability samples 4. study population: group of autoimmune hepatitis: patients with definite autoimmune hepatitis or their healthy households for controls group of primary biliary cholangitis: patients with definite primary biliary cholangitis or their healthy households for controls group of primary sclerosing cholangitis: patients with definite primary sclerosing cholangitis or their healthy households for controls group of non-alcoholic steatohepatitis: patients with definite non-alcoholic steatohepatitis or their healthy households for controls group of liver abscess: patients with definite liver abscess or their healthy households for controls.

Eligibility criteria:
inclusion criteria: * adults aged 19 years and older diagnosed with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, or liver abscess, who have consented to participate in this study at chungnam national university hospital. * adults aged 19 years and older, who are cohabitants of patients diagnosed with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, or liver abscess, and have consented to participate in this study at chungnam national university hospital. b. exclusion exclusion criteria: * individuals under the age of 19. * patients or guardians who do not consent to participate in the study

Keywords: liver diseases microbiota immune system
effect of propofol on postoperative sleep quality in elderly patients with sleep disorders

Conditions: Sleep Disorder

Summary: this study intends to conduct postoperative sleep intervention for elderly patients with sleep disorders undergoing surgery. we hope to explore whether propofol can improve the postoperative sleep quality of elderly patients with sleep disorders, prevent the occurrence of postoperative delirium in elderly patients, relieve patients' pain, promote patients' postoperative rehabilitation, and provide reference for realizing the rapid rehabilitation of elderly patients with sleep disorders through intravenous administration of research drugs, on the premise of improving patient comfort and ensuring patient safety.

the purpose of this multicenter, randomized, controlled clinical study was to evaluate the efficacy and safety of propofol compared with normal saline and dexmedetomidine in the effect of postoperative sleep quality in elderly subjects with sleep disorders. subjects were randomly assigned to propofol group, dexmedetomidine group or normal saline control group. propofol group: at 21:00 on the night of tracheal extubation, propofol was administered intravenously. moaas/s was used to evaluate subjects 30 seconds after the end of administration.dexmedetomidine group: treated with dexmedetomidine at 21 pm on the day of tracheal extubation. during administration, patients were evaluated with moaa/s every 2min. normal saline control group: 21 on the night of tracheal extubation: normal saline was injected intravenously at the rate of 0.5ml/(kg.h) beginning at 00. during the administration, patients were evaluated with moaa/s every 2min. the effect of drugs on sleep improvement was evaluated by subjective scale and objective electrical monitoring.

Eligibility criteria:
inclusion criteria: * age ≥ 60 years old * chronic insomnia * pittsburgh sleep quality index\>5 points * daytime functional impairment (component ⅶ ≥2 points in psqi) * patients undergoing elective surgery * patients to be admitted to icu after surgery * voluntarily participate in the study and sign the informed consent exclusion criteria: * subjects with severe hemodynamic instability * subjects with difficult airway * patients with other sleep disorders (including sleep apnea syndrome, exercise-related sleep disorders and other types of sleep disorders) * subjects requiring sedation, mechanical ventilation, or sleep prior to medication; * severe liver dysfunction (child-pugh grade c) * severe renal dysfunction (requiring dialysis before surgery) * patients with allergies to study drugs and related ingredients * patients with severe dementia, low cognitive function, language impairment, severe hearing or vision impairment, mental disorder, coma and other conditions cannot complete the assessment

Keywords: sleep disorder propofol dexmedetomidine